Much of modern digital society now rests on advanced silicon chips made by just two manufacturers—and there is no road back.
With the pandemic accelerating internet wagering’s spread around the world, a handful of seasoned global players vie with new regulation and competition to take their game to the next level.
After a pair of stunning announcements, two biotech upstarts take a big step toward approval, and toward potentially charting a less-travelled path to long-term profitability.
After decades of 70% growth spurts, vicious price wars, and a major price-fixing scandal, memory chips show signs of behaving, dare we say, almost like a stable business.
How new regulations and direct-to-consumer distribution models play out for the hearing industry is—much like these tiny marvels of technology themselves—likely to be complicated.
As the candidates hurtle toward the finish line, modelling the long-term profits for one of the most audacious undertakings in the history of science remains a separate challenge.
China was the first country to confront COVID-19 and appears to be the first to recover. The solidarity and tenacity of the Chinese people were key reasons for the success, writes Harding Loevner Analyst Jingyi Li.
Consumer goods companies are being pressured to reduce or eliminate single-use plastics from product packaging. This presents an opportunity and a challenge. One thing seems certain: companies that ignore demands for eco-friendly packaging do so at their peril.
In response to China’s decision to halt plastic scrap imports, some waste management companies in the West are going high tech.
Pharmaceutical companies, pressured by buyers to lower drug prices, find their high profit margins threatened.
Selling software as a service instead of a product has been a boon for enterprise software companies. But will their growth translate to high profits?
A Prescription for Growth? Why Pharma Companies Are Testing New Tactics to Refill Their Drug Pipelines
Many pharmaceutical companies are shifting away from large acquisitions, instead opting to buy smaller firms with riskier, earlier-stage drug candidates. Others are experimenting with new strategies altogether.